Crexendoの空売り状況は、投資家がCrexendoの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Crexendo (NASDAQ:CXDO) 株価情報, 空売り情報

Crexendo

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of revenue from the Cloud telecommunications segment.

Crexendo Inc

Sangoma Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STC#TSX">STC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $59.10 million which missed the analyst consensus estimate of $63.18 million by 6.46 percent. This is a 5.10 percent decrease over sales of $62.28 million the same period last year.

Earnings

Earnings Misses

News

TSX:STC

Sangoma Technologies Q2 EPS $(0.06) Misses $(0.03) Estimate, Sales $59.10M Miss $63.18M Estimate

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) annnounced its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/n43509453/viking-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corpor">details from the report.&nbsp;</a>
The Details:&nbsp;Viking Therapeutics reported quarterly losses of&nbsp;32 cents&nbsp;per share, which missed the analyst consensus estimate for losses of 28 cents. The company reported losses of&nbsp;25 cents&nbsp;per share in the same period last year.
Viking reported a net loss of&nbsp;$35.4 million in the fourth quarter, compared to a net loss of&nbsp;$24.6 million, in the corresponding period in 2023.
Research and development expenses for the year ended Dec. 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for drug candidates, stock-based compensation and salaries and benefits, partially offset by a decrease in expenses related to clinical studies and preclinical studies.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details"> Ford Shares Skid After Q4 Report: Details</a>
&#8220;2024 was an exciting and extremely productive year for Viking,&#8221; stated Brian Lian, Ph.D., CEO of Viking. 
&#8220;During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for the treatment of MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data,&#8221; Lian said. 
VKTX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop&nbsp;</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Health Care

After-Hours Center

Movers

General

VKTX

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates

McStarlite is a provider of complex sheet metal aerospace components. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. McStarlite Co. will be reported as part of Standex's Engineering Technologies Group business segment. In calendar year 2024, McStarlite revenue was approximately $33 million with an adjusted EBITDA margin above 20%.&nbsp;

Standex Acquires Privately-Held, California-Based McStarlite For $56.5M Cash

Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) is looking for Q1 Adj EPS of $0.06-0.11 vs $0.42 analyst estimate. sees sales of $70.000 million-73.000 million vs $92.91 million estimate.

Guidance

Impinj Sees Q1 Adj EPS $0.06-0.11 vs $0.42 Est; Sees Sales $70.000M-73.000M vs $92.91M Est

Gold production in 2025 reflects the following:
<ul>
<li>First production from Skouries in 2026 rather than 2025.</li>
<li>At Kisladag, expected production has been impacted by longer than planned leach cycles and lower grade stacked.</li>
<li>At Olympias, expected production has been impacted by a delay in mill expansion commissioning to 650ktpa, and unscheduled maintenance of the gold concentrate filters.</li>
</ul>
"Our updated 2025 gold production guidance is expected to be between 460,000 and 500,000 ounces. This has been lowered from our prior outlook provided in 2024 to reflect the change in initial production at Skouries from the third quarter of 2025 to the first quarter of 2026. In addition, guidance at both Kisladag and Olympias has been lowered compared to our prior 2025 guidance provided in 2024," the company said.&nbsp;

Eldorado Gold Updates 2025 Gold Production Guidance To 460,000 - 500,000 Ounces; Now Expects First Production At Skourie In Q1 Of 2026 Rather Than 2025

Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) reported quarterly earnings of $0.48 per share which met the analyst consensus estimate. This is a 433.33 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $91.57 million which missed the analyst consensus estimate of $92.95 million by 1.49 percent. This is a 29.61 percent increase over sales of $70.65 million the same period last year.

Impinj Q4 Adj $0.48, Inline, Sales $91.57M Miss $92.95M Estimate

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Trading Halt: Halted at 5:30:17 p.m. ET - Trading Halt: Halt News Pending

The Company announced in September 2024 that the signal-finding study met its primary endpoint. Next steps will be guided by regulatory discussions and on-going long term extension study.

RXRX

Recursion Reports 12 Month Data From Phase 2 Study (Sycamore) Of REC-994 At International Stroke Conference

The company reported net sales of $19.51 billion for the retail month of January, the four weeks ended February 2, 2025, an increase of 9.2 percent from $17.87 billion last year.
Net sales for the first 22 weeks were $113.55 billion, an increase of 8.2 percent from $104.94 billion last year.

COST

Reported Earlier, Costco Wholesale January Comparable Sales Up 7.5%

FormFactor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) shares are diving in extended trading Wednesday after the company reported fourth-quarter financial results that came up short <a href="https://www.benzinga.com/pressreleases/25/02/g43509179/formfactor-inc-reports-2024-fourth-quarter-results">of analyst expectations</a>.
<ul>
<li>Q4 Revenue: $189.48 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $191.12 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 27 cents, versus estimates of 29 cents</li>
</ul>
Total revenue was up 12.7% on a year-over-year basis. FormFactor said High Bandwidth Memory grew fourfold in fiscal 2024 compared to the prior year, driven by adoption of generative AI. DRAM probe-card revenue&nbsp;continued to climb in the quarter, reaching record levels for the third straight quarter.
&#8220;As expected, FormFactor reported sequentially lower fourth-quarter revenue, gross margin, and non-GAAP earnings per share, driven by the forecasted reduction in Foundry &amp; Logic probe-card revenue,&#8221; said Mike Slessor, CEO of FormFactor. &#8220;This was partially offset by growth in DRAM probe-card revenue, with HBM increasing to approximately half of DRAM revenue.&#8221;
FormFactor also announced that the company and MBK Partners are acquiring FICT Limited from Advantage Partners. FormFactor will invest $60 million and receive a 20% minority stake and a seat on the company&#8217;s board. 
&#8220;FormFactor&#8217;s investment in FICT builds on our long-term collaboration with them as a supplier of the industry-leading, high-performance components we use in our advanced probe cards, and provides a platform for accelerated development of tomorrow&#8217;s test and packaging consumables,&#8221; Slessor added.
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43511849/strategy-q4-earnings-bitcoin-treasury-company-spends-205b-on-btc-shares-inch-higher-despite-revenue-miss">Strategy Q4 Earnings: Bitcoin Treasury Company Spends $20.5B On BTC, Shares Inch Higher Despite Revenue Miss</a>
Outlook: FormFactor expects first-quarter revenue to be in the range of $165 million to $175 million versus estimates of $195.81 million. The company anticipates first-quarter adjusted earnings of 3 cents to 11 cents per share, versus estimates of 33 cents per share. 
FormFactor noted it has continued to see &#8220;slow demand&#8221; in high-volume markets like client PCs and mobile handsets in the first quarter. Despite the slowing demand, the company anticipates an overall demand increase for its products throughout 2025.
FORM Price Action: FormFactor shares were down 22.81% after hours, trading at $31.74 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using AI from MidJourney.

FORM

FormFactor Stock Falls On Q4 Earnings Miss, Weak Guidance As 'Slow Demand' Continues In Q1

S&amp;P 500 constituent Lennar Corp is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7.&nbsp;
Following the spin-off, Lennar will remain in the S&amp;P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&amp;P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space.

IRWD

MRPw

Millrose Properties To Replace Ironwood Pharmaceuticals In S&P SmallCap 600, Effective Prior To  Opening Of Trading On February 10

Associated Capital Group Q4 EPS $0.20 Down From $0.76 YoY, Sales $5.15M Down From $5.64M YoY

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has outperformed the market over the past 5 years by 11.31% on an annualized basis producing an average annual return of 23.81%. Currently, Apple has a market capitalization of $3.49 trillion. 
Buying $100 In AAPL: If an investor had bought $100 of AAPL stock 5 years ago, it would be worth $289.19 today based on a price of $232.23 for AAPL at the time of writing.
<h3>Apple's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738793813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

AAPL

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

WIIM

Rayonier shares are trading higher after the company reported Q4 earnings above estimates.

Helmerich & Payne shares are trading lower after the company missed Q1 revenue expectations.

PLUS

ePlus shares are trading lower after the company lowered its FY25 revenue guidance.

Hillenbrand shares are trading lower after the company cut its FY25 earnings and revenue guidance.

CNMD

Conmed shares are trading lower after the company issued FY25 earnings and revenue guidance below estimates.

TTMI

TTM Technologies shares are trading higher after the company reported Q4 earnings and revenue above estimates.

The Trump administration on Wednesday dialed back elements of its controversial proposal to <a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">assume control over Gaza</a>, following immediate global backlash. 
Officials are now clarifying that President Donald Trump's suggestion to <a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">relocate Palestinians and redevelop Gaza</a> was not a commitment to deploying U.S. troops or spending American taxpayer dollars. The New York Times <a href="https://www.nytimes.com/live/2025/02/05/world/israel-gaza-netanyahu-trump">reports </a>that key figures within the administration are emphasizing a more limited role in the plan.
What Happened: After unveiling the proposal during Israeli Prime Minister Benjamin Netanyahu's White House visit, Trump's vision for a transformed Gaza ignited international opposition. The plan, which involved relocating up to two million Palestinians and redeveloping the area into a U.S.-controlled territory, was swiftly rejected by Middle Eastern leaders and global institutions, citing violations of international law. 
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43506109/bill-ackman-sends-unitedhealth-stock-lower-with-deleted-tweet-heres-what-he-said">Bill Ackman Sends UnitedHealth Stock Lower With Deleted Tweet: Here&#8217;s What He Said</a>
Secretary of State Marco Rubio later stated that Trump was merely suggesting reconstruction efforts rather than permanent U.S. governance over Gaza, The Times reported.
Special envoy Steve Witkoff echoed this sentiment, assuring Republican senators that Trump had no intention of putting "troops on the ground" or allocating federal funds to the effort.
Saudi Arabia issued a statement before dawn, rejecting any forced displacement of Palestinians and reaffirming that diplomatic ties with Israel remain conditional on an independent Palestinian state. Egypt and Jordan also condemned any plans to remove Gaza's population, with Jordan's King Abdullah II reaffirming his opposition in a meeting with Palestinian leadership.
Why It Matters: Trump's Gaza remarks disrupted diplomatic efforts and injected uncertainty into U.S. foreign policy in the Middle East. Beyond the immediate regional implications, market observers linked the proposal to rising demand for safe-haven assets. 
Palestinians in Gaza expressed both outrage and uncertainty, with some rejecting forced relocation outright and others citing the dire conditions caused by prolonged conflict as a reason to consider leaving. Hamas outright rejected the proposal, warning that any forced relocation would escalate tensions in a region, according to the NY Times.
Meanwhile, Gold prices <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43485292/gold-outshines-bitcoin-as-trumps-gaza-plan-us-china-tensions-fuel-rally-peter-schiff-calls">soared to a record $2,849.05 per ounce</a> as investors responded to geopolitical instability and renewed U.S.-China tensions. Economist Peter Schiff framed the surge as a contrarian signal, arguing that broader retail interest in gold is yet to come.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43502963/oil-drops-as-traders-doubt-iran-sanctions-trump-bark-is-far-worse-than-his-bite-analyst-says">Oil Drops As Traders Doubt Iran Sanctions: &#8216;Trump Bark Is Far Worse Than His Bite,&#8217; Analyst Says</a></li>
</ul>
Photo: Chip Somodevilla/Shutterstock.com

Government

Global

Trump Administration Softens Gaza Takeover Proposal As Middle East Allies Reject Plan

The company said, "Crexendo (CXDO) wrapped up its most successful Codefest to date as part of its annual User Group Meeting in Nashville, TN. The h...

Crexendo says Codefest drew 'record participation'

Lake Street analyst Eric Martinuzzi maintained a Buy rating on Crexendo (CXDO – Research Report) today and set a price target of $7.00. The company...

Crexendo (CXDO) Receives a Buy from Lake Street

Crexendo Non-GAAP EPS of $0.06 beats by $0.01, revenue of $15.6M beats by $0.46M

Crexendo Inc. ( ($CXDO) ) has released its Q3 earnings. Here is a breakdown of the information Crexendo Inc. presented to its investors. Crexendo, ...

Crexendo Reports Strong Q3 2024 Financial Growth

Crexendo, Inc. (CXDO) Q3 2024 Earnings Call Transcript

B. Riley raised the firm's price target on Crexendo (CXDO) to $6.75 from $6 and keeps a Buy rating on the shares following the "solid" Q3 report. P...

Crexendo price target raised to $6.75 from $6 at B. Riley

Crexendo (CXDO) announced that Akabis has selected Crexendo's NetSapiens Platform as its next-generation solution to replace their Microsoft (MSFT)...

Crexendo selected by Akabis to replace Microsoft Metaswitch platform

Crexendo: Microsoft's Exit Relieves Competitive Pressures

Undercovered Dozen: Arqit Quantum, CleanSpark, Sezzle, STAG Industrial +

Crexendo (CXDO) announced the release of v44.2 of the Crexendo NetSapiens Platform. This release introduces a suite of AI features at its core, ena...

Comments

Crexendo

空売り

Crexendo (NASDAQ:CXDO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル